Navigation Links
Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH

) +44 (0) 207 107 0611 (U.K.) Webcast - Live and replay on demand Actelion webcasts its Investor Conference Call. On the Web, you may either follow the call live or have the call replayed later on demand. To access the webcast live, simply visit the link on our homepage http://www.actelion.com/ 5-10 minutes before the conference is due to start, or copy the following link into your browser: http://gaia.world-television.com/actelion/20070305/trunc/ Approximately 60 minutes after the call has ended, the archived investor webcast will be available for replay through our homepage. After 19 March 2007, it will be stored under Investors/Past Events


'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Actelion Announces Positive Study with Bosentan Tracleer CTEPH
(Date:10/5/2008)...w England Journal of Medicine reaffirm,well-establ...RIVA(R),HandiHaler(R), RIDGEFIELD, Conn., and NEW...T (Understanding Potential Long-term Impacts on Fu...(R) HandiHaler(R) (tiotropium bromide,inhalation p...r up to 4,years as measured by FEV(1) (p<0.001) ve...
(Date:10/2/2008)...PC clinical success and expanded reimbursement ..., Oct. 2 /- Uroplasty, Inc.... first patients in a new,randomized, controlled mu...,PC neuromodulation system for the treatment of ov..., urge incontinence and frequency of urinary,voids...
(Date:10/2/2008)...RNewswire/ -- Athera Biotechnologies AB and Dyax,C...e entered into a,collaboration to discover and to ... treatment of cardiovascular inflammatory diseases...on of work by Athera,scientific founders, Professo...tutet. The research links naturally occurring anti...
(Date:10/1/2008)...1 /- Ironwood Pharmaceuticals, Inc.,t...ate equity financing.,This capital will be utilize...am evaluating linaclotide for the treatment of irr...d chronic constipation (CC), to invest,in a growin...s, and to,expand commercial capabilities. The fina...
Breaking Medicine Technology:Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 2Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 3Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 4Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 6Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial 2Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial 3Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial 4Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3 2Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3 3Plexus Systems Ranks in Top Third of the 2007 Inc 5 000 with Three Year Sales Growth of 226 25 730 1Plexus Systems Ranks in Top Third of the 2007 Inc 5 000 with Three Year Sales Growth of 226 25 730 2Plexus Systems Ranks in Top Third of the 2007 Inc 5 000 with Three Year Sales Growth of 226 25 730 3Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences 727 1Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 1Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 2Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 3Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 4Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 5Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 6Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 7Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 8Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 9Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 10Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 11Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 12Minimally Invasive Heart Surgery Research Wins N I H Award 721 1Minimally Invasive Heart Surgery Research Wins N I H Award 721 2
...TAWA, Canada – March 7, 2007 – Liponex...alizing in developing,advanced products related to...uo;good cholesterol,” today announced result...duct, CRD5. CRD5 is,being developed for the treatm...showed, to date, that CRD5 was safe and that the d...
...reduced the number of,new or enlarged lesions comp...tion at upcoming medical meeting -, CAMBRIDGE, Mas...-FirstCall/ -- Biogen Idec, Inc. and PDL BioPharma...CE trial, a Phase 2,randomized, double-blind, pla...ry endpoint in relapsing multiple sclerosis (MS),p...
Other Medicine Technology:Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 2Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 3Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 2Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 3Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 4Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 5
(Date:10/6/2008)...DHC, a Web-based resource designed to engage and e...(CDHC) options including Health Savings Accounts (...exible Spending Accounts (FSAs), has partnered wit...e level services in concert with its existing dire... , MINNEAPOLIS (Business ...
(Date:10/6/2008)...re-USNewswire/ -- The United States has,intervened...hat they,submitted false claims to Medicare arisin...sham durable medical equipment (DME) suppliers, th...s are McKesson Corporation,McKesson Medical-Surgi...lden Gate Ancillary LLC, Beverly Enterprises Inc.,...
(Date:10/6/2008)... -- A special supplement of the Oct. 15,journal Ca...- and,middle-income countries to implement breast ...n disease among women worldwide., "Guidelines for...Implementation" developed by the Breast Health Glo...resource allocation -- based on countries,overall...
(Date:10/6/2008)...iew recently posted detailed information on its Ci...serious side effects caused by the drug and its fa...ential side effects are the development of fatal i...t and child patients. , D...e number one resource for everything and anything ...
Breaking Medicine News(10 mins):Health News: LearnCDHC Bridges Education Gap on Consumer Directed Healthcare : Interactive Web resource engages and educates consumers about consumer-directed healthcare 2Health News: LearnCDHC Bridges Education Gap on Consumer Directed Healthcare : Interactive Web resource engages and educates consumers about consumer-directed healthcare 3Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 2Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 3Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3
...omen had about a 20 percent lower chance of develo... new research bolsters the theory that the female ...al cancer. Dr. Carlo La Vecchia, who led the s...uspected that estrogen in the pill could protect a...
...re is poorly controlled. Drugs and lifestyle modif...rtension) yet these measures are not being taken b...he Baylor School of Medicine, Houston, Texas, doct...00 adults over 25 and found that 27 per cent had h...
...anization for Scientific Research (NWO) discovered...tance to disease if they took extra zinc in additi..., zinc was largely ignored due to the difficulty i...Scientists now know that zinc deficiency leads to ...
...er these days, wonder premature memory loss is no... too much work causing lack of concentration, memo...erations in memory and neurotransmitters are found...nson's disease and Alzheimer's disease. // The fun...
Other Medicine News:
This double ended instrument was designed to lift and manipulate the corneal flap in Lasik procedures. Manufactured in titanium.
Flat curved 1 mm spatula blade 30 mm long with marks at 5 mm, 6 mm and 7 mm from tip, polished finish and round knurled handle. Most popular size or model.
Short handled spatula for use through the side port stab incision. The malleable silver 0.5 mm tip can be shaped to the surgeon's preference for maximum control. Round serrated handle.
Used to mash overlooked pieces of nucleus into irrigating-aspirating unit and to control nucleus with second hand in phacoemulsification. 31 mm long narrow spatula blade. Round knurled handle with po
Medicine Products: